Needham & Company Remains Confident in Sarepta Therapeutic (SRPT) Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Sarepta (SRPT) PT Raised at Jefferies as BioMarin AdCom Viewed as a Positive But Remains Cautious
November 25, 2015 7:27 AM ESTJefferies analyst Gena Wang views the negative AdCom outcome for BMRN's drisapersen as a positive for Sarepta Therapeutic (NASDAQ: SRPT), although questions remain. As such the firm raised its price target to $38.00 (from $28.00) but maintained a Hold rating.
Wang commented, "We view negative... More
Why BioMarin FDA Panel is Positive for Sarepta (SRPT) - Oppenheimer
November 25, 2015 7:19 AM ESTOn Nov. 24, the FDA held an Advisory Committee panel for BioMarin's (NASDAQ: BMRN) Kyndrisa a potential competitor to eteplirsen. The panel highlighted Kyndrisa's significant liabilities and the panel focus included safety concerns then difficult-to-interpret efficacy data.
Why is this a positive for Sarepta... More
